Dr. Andre A. Konski
Claim this profileChester County Hospital
Studies Prostate Adenocarcinoma
Studies Prostate Cancer
5 reported clinical trials
18 drugs studied
Affiliated Hospitals
Clinical Trials Andre A. Konski is currently running
Apalutamide + Hormone and Radiation Therapies
for Prostate Cancer
This phase III trial studies whether adding apalutamide to the usual treatment improves outcome in patients with lymph node positive prostate cancer after surgery. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgens, or male sex hormones, can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may help stop or reduce the growth of prostate cancer cell growth by blocking the attachment of androgen to its receptors on cancer cells, a mechanism similar to stopping the entrance of a key into its lock. Adding apalutamide to the usual hormone therapy and radiation therapy after surgery may stabilize prostate cancer and prevent it from spreading and extend time without disease spreading compared to the usual approach.
Recruiting2 awards Phase 3
Hormone Therapy + Radiation
for Prostate Cancer
This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts of the body. Decipher score in this study is used for patient selection and the two variations of treatment to be studied: intensification for higher Decipher score or de-intensification for low Decipher score. Patients with higher Decipher risk score will be assigned to the part of the study that compares the use of 6 months of the usual treatment (hormone therapy and radiation treatment) to the use of darolutamide plus the usual treatment (intensification). The purpose of this section of the study is to determine whether the additional drug can reduce the chance of cancer coming back and spreading in patients with higher Decipher score. The addition of darolutamide to the usual treatment may better control the cancer and prevent it from spreading. Alternatively, patients with low Decipher risk score will be assigned to the part of the study that compares the use of radiation treatment alone (de-intensification) to the usual approach (6 months of hormone therapy plus radiation). The purpose of this part of the study is to determine if radiation treatment alone is as effective compared to the usual treatment without affecting the chance of tumor coming back in patients with low Decipher score prostate cancer. Radiation therapy uses high energy to kill tumor cells and reduce the tumor size. Hormone therapy drugs such as darolutamide suppress or block the production or action of male hormones that play role in prostate cancer development. Effect of radiation treatment alone in patients with low Decipher score prostate cancer could be the same as the usual approach in stabilizing prostate cancer and preventing it from spreading, while avoiding the side effects associated with hormonal therapy.
Recruiting2 awards Phase 31 criteria
More about Andre A. Konski
Clinical Trial Related4 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 2 Active Clinical TrialsTreatments Andre A. Konski has experience with
- Apalutamide
- Bicalutamide
- Buserelin
- Degarelix
- Flutamide
- Goserelin
Breakdown of trials Andre A. Konski has run
Prostate Adenocarcinoma
Prostate Cancer
Breast Cancer
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Andre A. Konski specialize in?
Andre A. Konski focuses on Prostate Adenocarcinoma and Prostate Cancer. In particular, much of their work with Prostate Adenocarcinoma has involved treating patients, or patients who are undergoing treatment.
Is Andre A. Konski currently recruiting for clinical trials?
Yes, Andre A. Konski is currently recruiting for 2 clinical trials in West Chester Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Andre A. Konski has studied deeply?
Yes, Andre A. Konski has studied treatments such as Apalutamide, Bicalutamide, Buserelin.
What is the best way to schedule an appointment with Andre A. Konski?
Apply for one of the trials that Andre A. Konski is conducting.
What is the office address of Andre A. Konski?
The office of Andre A. Konski is located at: Chester County Hospital, West Chester, Pennsylvania 19380 United States. This is the address for their practice at the Chester County Hospital.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.